

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 10, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
June 10, 2004	Steven L. Highlander
Date	

RECEIVED
JUN 14 AM 10:58
R/FINANCE

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: *U.S. Patent Application No. 10/759,897 entitle "METHODS AND COMPOSITIONS RELATING TO MUSCLE SPECIFIC SARCOMERIC CALCINEURIN-BINDING PROTEINS (CALSARCINS)" Eric N. Olson and Norbert Frey*
Our reference.: UTSD:729USD3

Sir :

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:729USD3.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Very truly yours,

Steve L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted

25421850.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric N. Olson and Norbert Frey

Serial No.: 10/759,897

Filed: January 16, 2004

For: METHODS AND COMPOSITIONS
RELATING TO MUSCLE SPECIFIC
SARCOMERIC CALCINEURIN-
BINDING PROTEINS (CALSARCINS)

Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: UTSD:729USD3

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

June 10, 2004

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:729USD3.

This application is a divisional application of Serial No. 10/045,594, filed November 7, 2001 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 10/045,594.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 10, 2004

Form PTO-1449 (modified)	Atty. Docket No. UTSD:729USD3	Serial No. 10/759,897
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Eric Olson Norbert Frey	
	Filing Date: January 16, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 96 12806 A	5-2-96	PCT			
	B2	WO 99 19473 A	4-22-99	PCT			
	B3	WO 01 53312 A	7-26-01	PCT			
	B4	WO 01 92567 A	12-6-01	PCT			
	B5	WO 02 04491 A	1-17-02	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ahmad et al., "Homo sapiens muscle-specific protein (C4 or C5)," Abstract, DATABASE EMBL 'Online!', Database Accession No. AF249873, 2000.
	C2	Ahmad et al., "Identification and characterization of a novel gene (C4orf5) located on human chromosome 4q with specific expression in cardiac and skeletal muscle," <i>Genomics</i> , 70:347-353, 2000.
	C3	Ding <i>et al.</i> , "Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin," <i>Circ Res.</i> , 84(6):729-734, 1999.
	C4	Faulkner et al., "FATZ: a filamin, actinin, and telethonin binding protein of the Z-disk of skeletal muscle," <i>Journ. Bio. Chem.</i> , 275:41234-41242, 2000.
	C5	Frey et al., "Calsarcins, a novel family of sarcomeric calcineurin-binding proteins," <i>Proc. Natl. Acad. Sci. USA</i> , 97:14632-14637, 2000.
	C6	Fuentes et al., "DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways," <i>Human Mol. Gen.</i> , Oxford University Press, U.K., 9:1681-1690, 2000.

25421848.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSD:729USD3	Serial No. 10/759,897
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Eric Olson Norbert Frey	
		Filing Date: January 16, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	GenBank accession number AA036142
	C8	GenBank accession number AA176945
	C9	GenBank accession number AA197193
	C10	GenBank accession number W29466
	C11	GenBank accession number AC008453.3
	C12	GenBank accession number AW000988
	C13	GenBank accession number AW742494
	C14	GenBank accession number AW964108
	C15	Alignment of SEQ. ID. No. 2 with SEQ. ID No. 286 of USSN 10/098,841, PGPUB No. 210020197679A1.
	C16	Hill <i>et al.</i> , "Cardiac hypertrophy is not a required compensatory response to short-term pressure overload," <i>Circulation</i> , 101(24):2863-2869, 2000.
	C17	Ievolella, "Homo sapiens mRNA for FATZ related protein 2 (ORF1)," Abstract, DATABASE EMBL 'Online!', EBI Database Accession No. AJ252149, 2000.
	C18	Lim <i>et al.</i> , "Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy," <i>Circulation</i> , 101(20):2431-2437, 2000.
	C19	Lim <i>et al.</i> , "Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition," <i>J Mol Cell Cardiol</i> , 32(4):697-709, 2000.
	C20	Marban <i>et al.</i> , "Intracellular free calcium concentration measured with 19F NMR spectroscopy in intact ferret hearts," <i>Proc Natl Acad Sci U S A</i> , 84:6005-6009, 1987.
	C21	Molkentin <i>et al.</i> , "A calcineurin-dependent transcriptional pathway for cardiac hypertrophy," <i>Cell</i> , 93:215-228, 1998.
	C22	Rothermel <i>et al.</i> , "A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling," <i>J. Bio. Chem.</i> , 275:8719-8725, 2000.
	C23	Seidman and Seidman, "Molecular genetic studies of familial hypertrophic cardiomyopathy," <i>Basic Res Cardiol.</i> ;93 Suppl 3:13-16, 1998.

25421848.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSD:729USD3	Serial No. 10/759,897
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Eric Olson Norbert Frey	
		Filing Date: January 16, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C24	Shimoyama <i>et al.</i> , "Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy," <i>Circulation</i> , 100(24):2449-2454, 1999.
	C25	Sussman <i>et al.</i> , "Prevention of cardiac hypertrophy in mice by calcineurin inhibition," <i>Science</i> , 281:1690-1693, 1998.
	C26	Zhang <i>et al.</i> , "Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats," <i>Circ Res.</i> , 84(6):722-728, 1999.

25421848.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.